|
<center>Panel Discussion: Venture Capital Investment in Early Stage Life Science Company
-This event is proudly hosted and co-sponsored by Baker Botts, LLP1
and co-sponsored by the New York City Bioscience Initiative2.</center> Lead panelists: Chau Khuong (OrbiMed), Will Shen (J&J) and Nick Wachtel (Lux Capital)
Venue: 44th Floor, 30 Rockefeller Plaza, New York, NY 10112
Time: 6:00pm � Thursday, November 6th Topics to be covered:
� What are the investment strategies of life science venture capital firms?
� How does the current credit crunch affect investment in early stage life science companies?
� How can biotech entrepreneurs make deals with VC?
� Who should early stage life science companies talk to, corporate or VC firms? About the lead panelists:
Chau Q. Khuong, Private Equity Principal, OrbiMed LLC. Mr. Khuong joined OrbiMed, which is the world's largest healthcare-dedicated investment firm with over $6 billion in assets under management, in 2003 to focus on biotechnology and medical device investments into both private equity and small capitalization public companies. Mr. Khuong holds a B.S. degree in Molecular, Cellular, and Developmental Biology (Concentration in Biotechnology) and a Master's in Public Health (Concentration in Infectious Disease), both from Yale University. He was actively involved in OrbiMed investments in Arius ...
Show More Details ...
| 
